Drugs / TTX-MC138-NODAGA-Cu64
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05908773 | Apr → Aug 2023 | neoplasm | TransCode Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTX-MC138-NODAGA-Cu64 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05908773 ↗ |
| Modality | Diagnostic / imaging agent | “developed as a PET radiopharmaceutical” NCT05908773 ↗ |
| Route | Intravenous | “Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously” NCT05908773 ↗ |